Heart Failure With Reduced Ejection Fraction and SGLT2 Inhibitors- Clinical Outcomes, Adverse Events, and Comorbidities Over Three Years: A Retrospective Cohort Study
Background: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors are now a cornerstone therapy for Heart Failure with reduced Ejection Fraction (HFrEF), with demonstrated benefits in survival and hospitalization reduction. However, most evidence is limited to 12–18 months of follow-up. Methods: We conducted a retrospecti...